Glaucoma filtering surgery (trabeculectomy) lowers eye pressure by draining fluid through a small fistula under the conjunctiva. However, normal wound healing can overdo it – fibroblasts invade and transform into myofibroblasts, producing excess collagen and scar tissue. This scarring can plug the new drainage (filtering bleb), causing surgical failure. Surgeons often use anti-scarring drugs like mitomycin C, but these can have serious side effects. Resveratrol, a natural compound in grapes and berries, is known for antioxidant and anti-inflammatory effects. Emerging evidence suggests resveratrol may also dampen fibrotic signals in tissues. This article reviews how resveratrol might modify pathways (like SIRT1 and TGF-β) that drive fibrosis in ocular tissues, evaluates its human safety and dosing, and considers how to test it after trabeculectomy. We summarize what is known about resveratrol’s effects on key scarring processes and how it might be used to help preserve the filtering bleb.

Fibrosis Pathways and Resveratrol’s Actions

After trabeculectomy, injury to the conjunctiva triggers a cascade of healing steps: inflammation, tissue proliferation, and remodeling. Very early on, inflammatory cells release TGF-β (transforming growth factor beta), a potent growth factor that drives fibroblasts to proliferate and become myofibroblasts. These myofibroblasts produce a dense extracellular matrix (collagen, fibronectin, etc.) and express contractile proteins. In the eye, this scar plugs the bleb so that fluid no longer drains properly () (). In essence, a tightly balanced scarring response is needed for a safe bleb – too much scar widens bleb wall closure and bleb failure, while too little scar can cause leaks or hypotony. Thus, controlling but not completely blocking these pathways is the goal.

Resveratrol can influence several molecular targets involved in fibrosis:

SIRT1 activation: Resveratrol is known to activate Sirtuin 1 (SIRT1), an enzyme that regulates gene expression. SIRT1 acts like a brake on fibrosis. In skin and organ fibrosis models, boosting SIRT1 sharply reduced collagen production and myofibroblast markers (). One study of human skin cells showed that activating SIRT1 (similar to resveratrol’s effect) almost completely blocked TGF-β-driven collagen synthesis and myofibroblast formation (). In mice with induced skin fibrosis, a SIRT1 activator halted and even reversed scarring. In short, SIRT1 naturally restrains the TGF-β/Smad fibrotic program, and resveratrol’s SIRT1 activation may impart these anti-fibrotic benefits ().

Inhibition of TGF-β/Smad signaling: (Transforming Growth Factor-β) is a key switch for fibrosis. When TGF-β binds receptors on fibroblasts, it activates Smad2/3 and SMAD4 proteins that move to the nucleus and turn on scar-making genes (collagen, fibronectin, alpha-smooth muscle actin). Resveratrol interferes with this cascade. In cultured trabecular meshwork cells, resveratrol reduced TGF-β1 levels and the activity of downstream Smad proteins (). It downregulated TGF-β1 and SMAD4 gene expression while upregulating the inhibitory SMAD7 (). Computer simulations suggest resveratrol binds with SMAD4’s MH2 domain, hindering the Smad complex from turning on fibrosis genes (). The result was dramatically lower production of collagens (type I, III, IV), fibronectin and α-SMA by those cells (). Other studies confirm this anti-TGF-β effect: in human ocular fibroblasts (from pterygium tissue), resveratrol blocked TGF-β1–induced fibrosis. It dose-dependently suppressed TGF-β1-induced collagen I, fibronectin and α-SMA expression (), and weakened Smad3 and other signaling (MAPK, PI3K/AKT) activation (). In summary, resveratrol disrupts the canonical TGF-β/Smad fibrotic signals, tipping the balance away from excessive matrix production () ().

Suppression of myofibroblast differentiation: Myofibroblasts are the main scar-making cells (they generate contractile fibers and collagen). TGF-β drives fibroblasts to become myofibroblasts (marked by α-SMA). By blocking TGF-β signaling, resveratrol reduces this transformation. In pterygium fibroblasts, resveratrol not only cut α-SMA and collagen expression () but also inhibited fibroblast proliferation, migration, and the contractile (wound-closing) behavior induced by TGF-β (). In skin-wound studies, topical or injected resveratrol improved healing with thinner scars. A review of skin wound models found resveratrol counteracted excessive scarring (). In animal models of hypertrophic scars, resveratrol treatment reduced collagen levels and α-SMA in scar fibroblasts (). Together, these data suggest resveratrol keeps fibroblasts from fully becoming stubborn myofibroblasts.

In sum, resveratrol acts on multiple levels of the fibrotic wound-healing cascade. It activates SIRT1 (which inherently suppresses fibrotic gene programs) and directly interferes with TGF-β/Smad signaling and related pathways. This dual action both slows new scar synthesis (lowering collagen and α-SMA expression) and enhances matrix breakdown by boosting enzymes like tPA (shifting toward tissue remodeling). The net effect in cell studies is less collagenous matrix made and more degraded, which could keep a filtering bleb more open () (). The challenge is ensuring enough healing for bleb stability but avoiding over-suppression that leads to bleb leaks.

Resveratrol Effects in Ocular Cells and Tissues

Although much of the research on resveratrol’s antifibrotic action comes from general wound-healing models, several studies have directly tested resveratrol in eye-related cells:

Trabecular meshwork cells: Human trabecular meshwork (TM) cells are responsible for draining fluid from the eye. In glaucoma, steroid exposure or other factors increase collagen in the TM, blocking outflow. Abu Bakar et al. treated cultured human TM cells with dexamethasone (to mimic glaucomatous stress) and resveratrol. Resveratrol (12.5 μM) significantly reversed the steroid-induced rise in collagen I, III, IV, fibronectin and α-SMA at both gene and protein levels (). It achieved this by lowering TGF-β1 and SMAD4 expression and raising SMAD7 (an inhibitor), as noted above (). These changes were accompanied by increased levels of tissue plasminogen activator (tPA) and reduced plasminogen activator inhibitor-1 – markers of a shift toward matrix degradation (). In functional terms, this was linked to improved outflow in animal studies. The TM cells showed no toxicity at these doses (), supporting feasibility of targeting TM fibrosis with resveratrol ().

Conjunctival fibroblasts: After trabeculectomy, the conjunctiva and Tenon’s capsule under the bleb are the main sites of scarring. Human Tenon’s fibroblasts have not been studied with resveratrol specifically, but similar cells have. In human pterygium fibroblasts (surplus conjunctival tissue often removed during eye surgery), Jiang and colleagues found resveratrol dose-dependently suppressed TGF-β1–induced fibrotic activation (). This included lower expression of type I collagen, fibronectin and α-SMA, and blocked fibroblast proliferation and migration (). These ocular fibroblasts came from patients’ eyes, so they behave like conjunctival fibroblasts in surgery. Notably, resveratrol here also encouraged some fibroblast apoptosis when challenged with TGF-β1 (), suggesting it helps remove overactive cells.

Animal wound models: In mice with skin wounds or scar models, resveratrol applied topically or intradermally improved healing with less scarring (). While skin differs from the eye surface, the cell biology is analogous: reduced fibrosis in skin means resveratrol is modulating the same basic pathways (e.g. TGF-β, SIRT1) that likely apply to conjunctival wound healing too (). In one mouse burn-wound model, intradermal resveratrol suppressed markers of scarring (reduced collagen and α-SMA) and activated SIRT1 in the wound site (). These findings bolster the idea that resveratrol can “counteract excessive scarring” in injured tissues ().

Taken together, these data in ocular and analogous cells support the notion that resveratrol could mitigate bleb fibrosis by dampening the cellular processes that make scar tissue. The remaining question is whether systemic or local treatment in patients could achieve these beneficial molecular effects safely and at the right time in healing.

Safety, Dosing, and Drug Interactions

Resveratrol supplements are widely available over-the-counter (often 100–500 mg per capsule, typically from grape extract or Japanese knotweed). Human trials have tested much larger doses. In a landmark study of 40 healthy adults, volunteers took 0.5, 1.0, 2.5 or 5.0 g of resveratrol per day for 29 days (). All doses up to 5 g were generally well tolerated. Mild-to-moderate gastrointestinal symptoms (nausea, gas, cramping, diarrhea) were the only common side effects at 2.5–5.0 g (). No serious adverse events were observed and no abnormalities on blood tests were found (). Notably, the higher doses (2.5–5 g/d) often caused GI upset in nearly all volunteers, though symptoms resolved after stopping. Based on this and other reviews, an upper daily limit of about 1 g for

Support the show